A Plus Biotechnology CoTPE:6918 -1.59%71 Gross Margin % is 66.03% as of Dec. 2025, which is 3% below its 10-year median of 68.24. GuruFocus rates TPE:6918 with a GF Score™ of 71/100 and a GF Value™ of NT$87.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 804 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks better than 77.61% on this metric.
TPE:6918's Gross Margin % is ranked better than 77.61% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 51.985
vs TPE:6918: 68.60
A Plus Biotechnology Co had a gross margin of 66.03% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for A Plus Biotechnology Co was 2.30% per year.
A Plus Biotechnology Co (TPE:6918) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
A Plus Biotechnology Co had a gross margin of 66.03% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
A Plus Biotechnology Co Gross Margin % Related Terms
A Plus Biotechnology Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6918 vs ABT, SYK, MDT: Gross Margin % Comparison
For the Medical Devices subindustry, A Plus Biotechnology Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
A Plus Biotechnology Co (TPE:6918) has a Gross Margin % of 66.03% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on A Plus Biotechnology Co and its competitors. This is near median its historical median of 68.24. Over the past decade, A Plus Biotechnology Co's Gross Margin % has ranged from 60.37 to 72.27. According to the industry distribution chart, A Plus Biotechnology Co ranks #180 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 22.4%.
Is A Plus Biotechnology Co's Gross Margin % too high?
A Plus Biotechnology Co's current Gross Margin % of 66.03% is near median its 10-year median of 68.24. Over the past 10 years, this metric has ranged from a low of 60.37 to a high of 72.27. The Medical Devices & Instruments industry median Gross Margin % is 51.99. A Plus Biotechnology Co's value of 66.03% is 27% above this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #180 out of 804 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, A Plus Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #180 out of 804 companies for Gross Margin %. This places A Plus Biotechnology Co in the top 22% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 51.99. A Plus Biotechnology Co's value of 66.03% is 27% above this benchmark. Historically, A Plus Biotechnology Co's own Gross Margin % has ranged from 60.37 to 72.27 over the past decade. While the company's 10-year median is 68.24 vs. the industry median of 51.99, A Plus Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 51.99, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current Gross Margin % of 66.03% is 27% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 51.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current Gross Margin % is 66.03%, which is near median its own 10-year median of 68.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.15, compared to a current price of NT$74.30 — trading 14.7% below its estimated fair value. The current Gross Margin % is 66.03%, which is near median its 10-year median of 68.24 and 27% above the Medical Devices & Instruments industry median of 51.99. A Plus Biotechnology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Gross Margin % is 66.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$74.30 is trading 14.7% below its estimated GF Value™ of NT$87.15.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
Gross Margin %: 66.03% (near median its 10-year median of 68.24)
GF Value™: NT$87.15 vs. price of NT$74.30 (14.7% below fair value)
Industry Position: 27% above the Medical Devices & Instruments median (#180 of 804)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
71GF Score
Get the complete analysis for TPE:6918
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
